

EXPAND ACCESS TO BIOMARKER TESTING IN TENNESSEE


THE RIGHT TREATMENT AT THE RIGHT TIME

WHAT IS BIOMARKER TESTING?


Biomarker testing is often used to help determine the best treatment for a patient.

- It is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker.
- Biomarker testing is an important step for accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.
- While most current applications of biomarker testing are in oncology and autoimmune disease, there is research underway to benefit patients with other conditions including heart disease, Alzheimer's disease, and other neurological conditions, rare disease, infectious disease and respiratory illness.

THE IMPORTANCE OF BIOMARKER TESTING



Of the 198 oncology drugs approved between 1998 and 2022 require biomarker testing prior to use¹



Of cancer clinical trials involved biomarkers²

BIOMARKER TESTING & HEALTH EQUITY

- **Not all communities in [STATE] are benefiting from the latest advancements in biomarker testing and precision medicine.**
 - Patients who are older, Black, uninsured or Medicaid-insured, are less likely to be tested for certain guideline-indicated biomarkers.
 - There are lower rates of testing in community settings versus academic medical centers.

THE BOTTOM LINE


Access to appropriate biomarker testing may help to achieve:

- better health outcomes
- improved quality of life
- reduced costs

Insurance coverage for biomarker testing is failing to keep pace with innovation and advancement in treatment.

- Without action, this could increase existing disparities in health outcomes by race, ethnicity, income and geography.

Twenty states including Kentucky, Georgia and Texas have recently passed legislation to expand coverage of biomarker testing.



Of oncology providers reported that insurance coverage is a **significant or moderate barrier** to appropriate biomarker testing for their patients³

In Tennessee:



OF COMMERCIAL INSURANCE PLANS PROVIDE COVERAGE THAT IS MORE RESTRICTIVE THAN NATIONAL COMPREHENSIVE CANCER NETWORK⁴ GUIDELINES

EXPAND ACCESS TO BIOMARKER TESTING IN TENNESSEE

What exactly is biomarker testing? Use the QR code to view a brief explainer video or visit: fightcancer.org/biomarkers to learn more!



SUPPORTERS OF TENNESSEE BIOMARKER TESTING LEGISLATION



¹Suehnholz SP, Nissan MH, Zhang H, et. al. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discov. 2023.

²The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications. Personalized Medicine Coalition, 2019.

³ACS CAN. "Survey Findings Summary: Understanding Provider Utilization of Cancer Biomarker Testing Across Cancers." December 2021.

⁴Wong WB, Anina D, Lin CW, and Adams D. Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. Per Med 2022; 10.2217/pme-2021-0174.

For more information please contact:

Maddie Michael, ACS CAN Tennessee Government Relations Director



Maddie.Bushnell@cancer.org



319-621-1795